KR20230003167A - 중추 신경계 전달 및 크립토코커스 감염의 치료를 위한 코클리에이트화된 항진균 화합물 - Google Patents

중추 신경계 전달 및 크립토코커스 감염의 치료를 위한 코클리에이트화된 항진균 화합물 Download PDF

Info

Publication number
KR20230003167A
KR20230003167A KR1020227041763A KR20227041763A KR20230003167A KR 20230003167 A KR20230003167 A KR 20230003167A KR 1020227041763 A KR1020227041763 A KR 1020227041763A KR 20227041763 A KR20227041763 A KR 20227041763A KR 20230003167 A KR20230003167 A KR 20230003167A
Authority
KR
South Korea
Prior art keywords
cochleate
antifungal
days
flucytosine
camb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227041763A
Other languages
English (en)
Korean (ko)
Inventor
라파엘 제이. 만니노
루잉 루
더그 에프. 클링
Original Assignee
마티나스 바이오파마 나노테크놀로지스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 filed Critical 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드
Publication of KR20230003167A publication Critical patent/KR20230003167A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227041763A 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스 감염의 치료를 위한 코클리에이트화된 항진균 화합물 Ceased KR20230003167A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662361351P 2016-07-12 2016-07-12
US62/361,351 2016-07-12
US201762513800P 2017-06-01 2017-06-01
US62/513,800 2017-06-01
PCT/US2017/041750 WO2018013711A1 (en) 2016-07-12 2017-07-12 Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections
KR1020197003873A KR20190029642A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스(cryptococcus) 감염의 치료를 위한 코클리에이트화된(encochleated) 항진균 화합물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197003873A Division KR20190029642A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스(cryptococcus) 감염의 치료를 위한 코클리에이트화된(encochleated) 항진균 화합물

Publications (1)

Publication Number Publication Date
KR20230003167A true KR20230003167A (ko) 2023-01-05

Family

ID=60952715

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227041763A Ceased KR20230003167A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스 감염의 치료를 위한 코클리에이트화된 항진균 화합물
KR1020197003873A Ceased KR20190029642A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스(cryptococcus) 감염의 치료를 위한 코클리에이트화된(encochleated) 항진균 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197003873A Ceased KR20190029642A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스(cryptococcus) 감염의 치료를 위한 코클리에이트화된(encochleated) 항진균 화합물

Country Status (8)

Country Link
US (3) US11123295B2 (enExample)
EP (1) EP3484447A4 (enExample)
JP (1) JP6991592B2 (enExample)
KR (2) KR20230003167A (enExample)
CN (2) CN114053417A (enExample)
AU (1) AU2017297402B2 (enExample)
CA (1) CA3027668A1 (enExample)
WO (1) WO2018013711A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6444865B2 (ja) 2012-07-30 2018-12-26 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド ダイズホスファチジルセリンで作られたコクリエート
JP2022544077A (ja) * 2019-08-13 2022-10-17 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド クリプトコッカス感染症を治療する方法
CN118370831A (zh) * 2023-01-20 2024-07-23 中国科学院微生物研究所 肌醇磷脂酰胺合成酶抑制剂与两性霉素b的联合用药及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925616A (en) * 1996-08-09 1999-07-20 Buckman Laboratories International, Inc. Treatment of fungal infections using a combination of an anti-fungal compound and an H-alkyl heterocyclic compound
US5837254A (en) * 1996-11-14 1998-11-17 Chen; Yu Method of treating candida and cryptococcus fungal infections by administering gentian
US6153217A (en) * 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
AUPQ066399A0 (en) 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
EP1259224A2 (en) 2000-01-24 2002-11-27 Biodelivery Sciences, Inc. Cochleate formulations and their use for delivering biologically relevant molecules
US20030219473A1 (en) 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
CA2504329C (en) 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
WO2004091578A2 (en) 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Novel encochleation methods, cochleates and methods of use
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
CA2585343C (en) * 2004-10-25 2016-06-21 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
WO2006109642A1 (ja) * 2005-04-07 2006-10-19 Toyama Chemical Co., Ltd. 医薬組成物および抗真菌剤を組み合わせて使用する方法
NZ565039A (en) * 2005-06-29 2010-04-30 Univ New York State Res Found Compositions and methods for less immunogenic protein-lipid complexes
US20100210575A1 (en) * 2007-06-29 2010-08-19 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
DE102008054431B3 (de) * 2008-12-09 2010-06-17 Pari Pharma Gmbh Aerosoltherapievorrichtung
WO2010091090A1 (en) * 2009-02-03 2010-08-12 Biodelivery Sciences International, Inc. Cochleate compositions and methods of use
WO2012151517A1 (en) 2011-05-05 2012-11-08 Coordinated Program Development, Llc Cochleate compositions and methods of making and using same
JP6444865B2 (ja) 2012-07-30 2018-12-26 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド ダイズホスファチジルセリンで作られたコクリエート

Also Published As

Publication number Publication date
CN109689028A (zh) 2019-04-26
US20210393526A1 (en) 2021-12-23
CA3027668A1 (en) 2018-01-18
CN114053417A (zh) 2022-02-18
AU2017297402B2 (en) 2023-02-09
KR20190029642A (ko) 2019-03-20
US20240423916A1 (en) 2024-12-26
US20200121601A1 (en) 2020-04-23
EP3484447A1 (en) 2019-05-22
WO2018013711A1 (en) 2018-01-18
JP2019520407A (ja) 2019-07-18
AU2017297402A1 (en) 2019-01-03
JP6991592B2 (ja) 2022-01-12
EP3484447A4 (en) 2020-07-22
US11123295B2 (en) 2021-09-21

Similar Documents

Publication Publication Date Title
US20240423916A1 (en) Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections
KR970007187B1 (ko) 개선된 암포테리신 b 리포좀 제조법
CN101267806B (zh) 缓释的抗感染药
JP5855829B2 (ja) リポソーム化バンコマイシン製剤
JP5920875B2 (ja) 真菌感染症を治療するための新規な製剤
US20230181759A1 (en) Compositions for treatment of viral respiratory infections and methods of use thereof
US9820940B2 (en) Liposomal formulations of polymyxin and uses thereof
WO2019213101A1 (en) Liposomal nano formulation of combinational antibiotics and the uses thereof
US20220313717A1 (en) Methods of treating cryptococcus infections
EP4572770A1 (en) Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis
US10092515B2 (en) Liposomal formulations of polymyxin B and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
A302 Request for accelerated examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000